Shionogi to acquire US biotech IntraBio for about ¥314bn

Shionogi is set to acquire US biotech IntraBio, which develops drugs for hereditary neurological disorders, for about ¥314bn, taking all of the company's shares. The deal is aimed at bringing in rare-disease talent and expertise to accelerate development of new drug candidates.

Detected & updated continuously · Source: Nebula